|
|
 |
|
Viewing report
|
|
|
|
Bioinformatics: The Next Generation of Market Opportunities
Drug and Market Development Publishing, March 2001, Pages: 400
Identification of targets for drug development and the discovery of therapeutics are being transformed by bioinformatics. D&MD's Bioinformatics Market Analysis Report assists in determining the best methods to incorporate and utilize bioinformatics to achieve and sustain a competitive advantage in this space. This Report examines the evolution of bioinformatics and the current status of the technology and its impending consequences.
Bioinformatics stands at the interface of molecular biology and information sciences, where it promises to provide critical tools for managing the immense volume of biological information. Last year, the Human Genome Project unlocked the DNA code for 23 human chromosomes. Contained within are millions of potential genetic markers for the development of new drugs and other treatments for disease. Making sense of all that data is the job of bioinformatics companies and requires some advanced computing muscle to do it.
The tools that comprise bioinformatics are themselves testament to the explosion of diversity that is present in the drug discovery industry. Just a few years ago, the only tractable experiments were intelligent chemical trial-and-error followed by extensive in vitro and in vivo testing. The 70's decade of analogue bashing gave way to the 80's rational drug design. The 90's revolution of biotechnology and new measurement technology has spawned new technologies and industries focused on in-silico and on-silico biology.
The prospects for bioinformatics are inseparable from the prospects and market structure of biotech, so a large amount of the equity investment in biotech during 2000, totaling $31 billion, flowed into bioinformatics. Overall, it is estimated that the pharma sector spends 6% of its $9 billion annual drug discovery budget on IT. That's $500 million per year. Suppliers such as MDL, Molecular Simulations, Tripos, and Oxford Molecular have grown and generate revenues between $20 million and $70 million. Oxford Molecular predicts a total market for its services totaling $1.3 billion by 2002 with 75% accessible from their own products. Other sources suggest an even larger market, moving to $10 billion in five years.
This Bioinformatics Report is the only report you need to carefully guide you through this competitive and challenging area.
Unique Benefits of this Report
» Up-to-date analysis of the various technologies, databases, and algorithms that are being deployed in bioinformatics today, giving insight into the current technology marketplace.
- Discussion of the market environment, including future predictions of technology trends of computer languages that are being used in the genomics-driven drug discovery landscape, detailing where the industry is going.
- Details of current venture capital breakout, presenting the market opportunities in bioinformatics.
- Comprehensive profiling of the leading players in the bioinformatics market, presenting unbiased analysis of the competitive environment.
- Analysis of the alliances and partnerships occurring to date, illustrating the successful strategies and collaborations.
Customers who bought this item also bought
Structure-Guided Drug Design: Rediscovering the Importance of Drug Structure for Drug Discovery
Preclinical Cancer Therapeutics 2007: Decoding Next Generation Drug Targets for Market Success
Alternative Power Generation in Germany
The Fourth Wave: A New Generation of Protein-Based Therapeutics
Coal Gasification for Power Generation - 4th Edition
World Bio-Informatics Market (2005-2010)
Systems Biology - Key to Unlocking the Value within the Omics Revolution
Geothermal Power Generation
|
|
|
|
